Cover Image
市場調查報告書

多形性膠質母細胞瘤(GBM):開發中產品分析

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229730
出版日期 內容資訊 英文 1321 Pages
訂單完成後即時交付
價格
Back to Top
多形性膠質母細胞瘤(GBM):開發中產品分析 Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016
出版日期: 2016年12月30日 內容資訊: 英文 1321 Pages
簡介

多形性膠質母細胞瘤(GBM),是最常見的惡性原發性腦瘤。GBM是由星狀神經膠細胞(形成保護大腦及脊髓內神經細胞的細胞)開始產生的。GBM由星形膠質細胞所構成。症狀有緩慢惡化的神經病變,通常是由於運動麻痺、頭痛、顱內增壓造成的全身症狀(頭痛、噁心、嘔吐、認知障礙、中風等)。治療方法包含放射線治療,化療等。

本報告提供多形性膠質母細胞瘤(GBM)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

多形性膠質母細胞瘤(GBM)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

中止開發的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8858IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial cells known as astrocytes. Signs and symptoms include slowly progressive neurologic deficit, usually motor weakness, headache, generalized symptoms of increased intracranial pressure, including headaches, nausea and vomiting, and cognitive impairment and seizures. Treatment includes radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 98, 53, 1, 4, 147, 18 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 8, 12, 1, 35 and 8 molecules, respectively.

Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (GBM) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Glioblastoma Multiforme (GBM) Overview
  • Therapeutics Development
  • Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies
  • Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes
  • Glioblastoma Multiforme (GBM) - Pipeline Products Glance
  • Glioblastoma Multiforme (GBM) - Products under Development by Companies
  • Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes
  • Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development
  • Glioblastoma Multiforme (GBM) - Therapeutics Assessment
  • Drug Profiles
  • Glioblastoma Multiforme (GBM) - Dormant Projects
  • Glioblastoma Multiforme (GBM) - Discontinued Products
  • Glioblastoma Multiforme (GBM) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2016
  • Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Development by Companies, H2 2016 (Contd..14)
  • Number of Products under Development by Companies, H2 2016 (Contd..15)
  • Number of Products under Development by Companies, H2 2016 (Contd..16)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Development by Companies, H2 2016 (Contd..21)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Activartis Biotech GmbH, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Advanced Accelerator Applications SA, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Advantagene Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Affimed GmbH, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Amal Therapeutics SA, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Ambrx Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Apac Biotech Pvt Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Apceth GmbH & Co KG, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by APIM Therapeutics AS, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Ariad Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Arog Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca Plc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Athenex Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Basilea Pharmaceutica Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Batu Biologics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Bayer AG, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by BeiGene Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals LLC, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Bio-Path Holdings Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Bioasis Technologies Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Biomar Microbial Technologies, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Bioncotech Therapeutics SL, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by BTG Plc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corp, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Cell Medica Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corp, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by CLL Pharma SA, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Critical Outcome Technologies Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by CTI BioPharma Corp, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Curadev Pharma Pvt Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Cynata Therapeutics Limited, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by CytoVac A/S, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by CytRx Corp, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by DEKK-TEC Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by DelMar Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by EirGenix Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by EntreChem SL, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Evotec AG, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by FirstString Research Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Five Prime Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Gene Techno Science Co Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Genentech Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Genisphere Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Genzyme Corp, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by GtreeBNT Co Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Hamlet Pharma AB, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Hutchison MediPharma Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Immatics Biotechnologies GmbH, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Immune Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Immunomedics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Immunomet Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Immupharma Plc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Incuron LLC, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Incyte Corp, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Infinity Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Inspyr Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by INSYS Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Intica Biomedical Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corp LLC, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Kalgene Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by KaloBios Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Kite Pharma Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Komipharm International Co Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Lentigen Technology Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by LinXis BV, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Lion Biotechnologies Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Loxo Oncology, Inc., H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Mabion SA, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by MacroGenics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Mateon Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by MedImmune LLC, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Merck KGaA, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Midatech Pharma Plc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by MimiVax LLC, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Moleculin Biotech Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Nanomerics Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Neonc Technologies Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Nerviano Medical Sciences Srl, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Neumedicines Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Neuralstem Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by NewLink Genetics Corp, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Novogen Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Nuo Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by NuvOx Pharma LLC, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Omniox Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Oncobiologics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Oncodesign SA, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Onconova Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Oncternal Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Orphagen Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Orphit SAS, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co KG, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Peloton Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by PharmAbcine Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by PharmaCyte Biotech Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Pharmicell Co Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by PIQUR Therapeutics AG, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Plex Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Progenics Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Puma Biotechnology Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Recepta Biopharma SA, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by ReNeuron Group Plc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Rexahn Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Rgenix Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Richter Gedeon Nyrt, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Rigontec GmbH, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Sanofi, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Sapience Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Scancell Holdings Plc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Sellas Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Sigma-Tau SpA, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by SignPath Pharma Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by SOM Biotech SL, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Sorrento Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by StemGen SpA, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Susavion Biosciences Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Symphogen A/S, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Therapeia GmbH & Co KG, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Theravectys SA, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Transgene SA, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Trillium Therapeutics Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Tyme Technologies Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Vault Pharma Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by VBI Vaccines Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by VCN Biosciences SL, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Vertex Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by ViraTherapeutics GmbH, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Ltd, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by Vyriad Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by X4 Pharmaceuticals Inc, H2 2016
  • Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..1), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..2), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..3), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..4), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..5), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..6), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..7), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..8), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..9), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..10), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..11), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..12), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..13), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..14), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..15), H2 2016
  • Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..16), H2 2016
  • Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2016
  • Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..1), H2 2016
  • Glioblastoma Multiforme (GBM) - Discontinued Products (Contd..2), H2 2016

List of Figures

  • Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2016
  • Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top